Proteins related to the spindle and checkpoint mitotic emphasize the different pathogenesis of hypoplastic MDS

Leukemia Research

Volumn 38, Issue 2, 2014, Pages 218-224

  Heredia, Fabiola Fernandes ^a   De Sousa, Juliana Cordeiro ^b   Junior, Howard Lopes Ribeiro ^b   Carvalho, Alex Fiorini ^c   Magalhaes, Silvia Maria Meira ^b   Pinheiro, Ronald Feitosa ^b  

^a Instituto do Cancer do Ceara   (Brazil)

^b FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^c A C CAMARGO CANCER CENTER   (Brazil)

Author keywords

AURKA; AURKB; CDC20; MAD2; Myelodysplastic syndromes

Indexed keywords

AURORA A KINASE; AURORA B KINASE; CELL CYCLE PROTEIN 20; CELL CYCLE PROTEIN;

ADOLESCENT; ADULT; AGE; ARTICLE; AURKA GENE; AURKB GENE; BONE MARROW CELL; CANCER PROGNOSIS; CDC20 GENE; CELL STRUCTURE; CYTOGENETICS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE AMPLIFICATION; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; M PHASE CELL CYCLE CHECKPOINT; MAD2L1 GENE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PATHOGENESIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; AGED; CELL CYCLE CHECKPOINT; CLASSIFICATION; GENETICS; KARYOTYPE; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; SPINDLE APPARATUS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CELL CYCLE CHECKPOINTS; CELL CYCLE PROTEINS; FEMALE; HUMANS; KARYOTYPE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; SPINDLE APPARATUS; YOUNG ADULT;

EID: 84892516363     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.11.003     Document Type: Article

References (31)

1. Yue G., Hao S., Fadare O., Baker S., Pozdnyakova O., Galili N., et al. Hypocellularity in myelodysplastic syndrome is an independent factor which predicts a favorable outcome. Leukemia Research 2008, 32:553-558.
2. Bejar R., Levine R., Ebert B.L. Unraveling the molecular pathophysiology of myelodysplastic syndromes. Journal of Clinical Oncology 2011, 29:504-515.
3. Molldrem J.J., Jiang Y.Z., Stetler-Stevenson M., Mavroudis D., Hensel N., Barrett A.J. Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles. British Journal of Haematology 1998, 102:1314-1322.
4. Jeng Y.M., Peng S.Y., Lin C.Y., Hsu H.C. Overexpression and amplification of Aurora-A in hepatocellular carcinoma. Clinical Cancer Research 2004, 10:2065-2071.
5. Lassmann S., Danciu M., Müller M., Weis R., Makowiec F., Schulte-Mönting J., et al. Aurora A is differentially expressed and regulated in chromosomal and microsatellite instable sporadic colorectal cancers. Modern Pathology 2009, 22:1385-1397.
6. Lin Z.Z., Jeng Y.M., Hu F.C., Pan H.W., Tsao H.W., Lai P.L., et al. Significance of Aurora B overexpression in hepatocellular carcinoma. Aurora B Overexpression in HCC. BMC Cancer 2010, 10:461.
7. Lucena-Araujo A.R., de Oliveira F.M., Leite-Cueva S.D., dos Santos G.A., Falcao R.P., Rego E.M. High expression of AURKA and AURKB is associated with unfavorable cytogenetic abnormalities and high white blood cell count in patients with acute myeloid leukemia. Leukemia Research 2011, 35:260-264.
8. Heredia F.F., de Sousa J.C., Carvalho A.F., Magalhaes S.M., Pinheiro R.F. Aurora-B expression may not contribute to disease progression: a reflection of the heterogeneous pathogenesis?. Haematologica 2012, 97:37-39.
9. Wang Z., Wan L., Zhong J., Inuzuka H., Liu P., Sarkar F.H., et al. Cdc20: a potential novel therapeutic target for cancer treatment. Current Pharmaceutical Design 2013, 19:3210-3214.
10. Yu L., Liu S., Guo W., Zhang B., Liang Y., Feng Q. Upregulation of Mad2 facilitates in vivo and in vitro osteosarcoma progression. Oncology Reports 2012, 28:2170-2176.
11. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088.
12. Malcovati L., Della Porta M.G., Strupp C., Ambaglio I., Kuendgen A., Nachtkamp K., et al. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica 2011, 96:1433-1440.
13. Thiele J., Kvasnicka H.M., Facchetti F., Franco V., Walt J., Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 2005, 90:1128-1132.
14. Chauffaille M.L.L.F., Yamamoto M., Moncau J.E., Braga G.W., Souto E.X., Kerbauy J. Cytogenetic abnormalities as prognostic factors in acute myeloid leukemia. Revista da Associação Médica Brasileira 1996, 42:200-204.
15. Malcovati L., Germing U., Kuendgen A., Della Porta M.G., Pascutto C., Invernizzi R., et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. Journal of Clinical Oncology 2007, 25:3503-3510.
16. Lorand-Metze I., Pinheiro M.P., Ribeiro E., de Paula E.V., Metze K. Factors influencing survival in myelodysplastic syndromes in a Brazilian population: comparison of FAB and WHO classifications. Leukemia Research 2004, 28:587-594.
17. Tong W.-G., Quintás-Cardama A., Kadia T., Borthakur G., Jabbour E., Ravandi F., et al. Predicting survival of patients with hypocellular myelodysplastic syndrome: development of a disease-specific prognostic score system. Cancer 2012, 118:4462-4470.
18. Lim Z.Y., Killick S., Germing U., Cavenagh J., Culligan D., Bacigalupo A., et al. Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin. Leukemia 2007, 21:1436-1441.
19. Greenberg P.L., Tuechler H., Schanz J., Sanz G., Garcia-Manero G., Solé F., et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012, 120:2454-2465.
20. Pinheiro R.F., Metze K., Silva M.R., Chauffaille Mde L. The ambiguous role of interferon regulatory factor-1 (IRF-1) immunoexpression in myelodysplastic syndrome. Leukemia Research 2009, 33:1308-1312.
21. Michel L.S., Liberal V., Chatterjee A., Kirchwegger R., Pasche B., Gerald W., et al. MAD2 haplo-insufficiency causes premature anaphase and chromosome instability in mammalian cells. Nature 2001, 409:355-359.
22. Sakakura C., Hagiwara A., Yasuoka R., Fujita Y., Nakanishi M., Masuda K., et al. Tumour-amplified kinase BTAKis amplified and overexpressed in gastric cancers with possible involvement in aneuploid formation. British Journal of Cancer 2001, 84:824-831.
23. Mondal G., Sengupta S., Panda C.K., Gollin S.M., Saunders W.S., Roychoudhury S. Overexpression of Cdc20 leads to impairment of the spindle assembly checkpoint and aneuploidization in oral cancer. Carcinogenesis 2007, 28:81-92.
24. Sotillo R., Hernando E., Díaz-Rodríguez E., Teruya-Feldstein J., Cordón-Cardo C., Lowe S.W., et al. Mad2 overexpression promotes aneuploidy and tumorigenesis in mice. Cancer Cell 2007, 11:9-23.
25. Pinto M., Soares M.J., Cerveira N., Henrique R., Ribeiro F.R., Oliveira J., et al. Expression changes of the MAD mitotic checkpoint gene family in renal cell carcinomas characterized by numerical chromosome changes. Virchows Archiv 2007, 450:379-385.
26. Li M., Fang X., Wei Z., York J.P., Zhang P. Loss of spindle assembly checkpoint-mediated inhibition of Cdc20 promotes tumorigenesis in mice. The Journal of Cell Biology 2009, 185:983-994.
27. Ouellet V., Guyot M.C., Le Page C., Filali-Mouhim A., Lussier C., Tonin P.N., et al. Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer. International Journal of Cancer 2006, 119:599-607.
28. Marucci G., Morandi L., Magrini E., Farnedi A., Franceschi E., Miglio R., et al. Gene expression profiling in glioblastoma and immunohistochemical evaluation of IGFBP-2 and CDC20. Virchows Archiv 2008, 453:599-609.
29. Park H.S., Park W.S., Bondaruk J., Tanaka N., Katayama H., Lee S., et al. Quantitation of Aurora kinase A gene copy number in urine sediments and bladder cancer detection. Journal of the National Cancer Institute 2008, 100:1401-1411.
30. Sorrentino R., Libertini S., Pallante P.L., Troncone G., Palombini L., Bavetsias V., et al. Aurora B overexpression associates with the thyroid carcinoma undifferentiated phenotype and is required for thyroid carcinoma cella proliferation. The Journal of Clinical Endocrinology and Metabolism 2005, 90:928-935.
31. Vischioni B., Oudejans J.J., Vos W., Rodriguez J.A., Giaccone G. Frequent overexpression of aurora B kinase, a novel drug target, in non-small cell lung carcinoma patients. Molecular Cancer Therapeutics 2006, 5:2905-2913.